Insider Selling: SiBone (NASDAQ:SIBN) SVP Sells $23,297.05 in Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 1,799 shares of SiBone stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $12.95, for a total transaction of $23,297.05. Following the completion of the sale, the senior vice president owned 284,175 shares in the company, valued at approximately $3,680,066.25. This represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

SiBone Price Performance

NASDAQ SIBN opened at $13.12 on Monday. SiBone has a 52 week low of $12.15 and a 52 week high of $21.89. The company has a current ratio of 8.55, a quick ratio of 7.21 and a debt-to-equity ratio of 0.20. The stock has a market cap of $579.51 million, a price-to-earnings ratio of -29.82 and a beta of 0.77. The company has a 50-day moving average price of $14.62 and a two-hundred day moving average price of $16.39.

SiBone (NASDAQ:SIBN) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09. The company had revenue of $56.35 million for the quarter, compared to analysts’ expectations of $56.26 million. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%. Analysts forecast that SiBone will post -0.78 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on SIBN shares. Needham & Company LLC boosted their price target on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. Wall Street Zen upgraded shares of SiBone from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. TD Cowen upped their price objective on shares of SiBone from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Finally, Canaccord Genuity Group raised their target price on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.67.

Institutional Investors Weigh In On SiBone

Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada boosted its stake in shares of SiBone by 98.5% during the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after acquiring an additional 736 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of SiBone by 0.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 225,001 shares of the company’s stock worth $4,437,000 after purchasing an additional 997 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of SiBone by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares during the last quarter. Larson Financial Group LLC boosted its position in shares of SiBone by 42.3% in the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock valued at $70,000 after purchasing an additional 1,061 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of SiBone by 4.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock valued at $733,000 after purchasing an additional 1,459 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.